In EGFR-mutated and ALK-rearranged lung cancer cell lines, MCL1 translocates to the nucleus and binds to FBW7 after TKI treatment, which leads to the degradation of MCL1 [32, 33]. This evidence concerns the gene ALK and lung cancer.